Antimicrobial Stewardship – Establishing An Effective Model For Australian Private Hospitals
Funder
National Health and Medical Research Council
Funding Amount
$55,807.00
Summary
Inappropriate and overuse of antibiotics in hospitals has accelerated world-wide antimicrobial resistance. Strategies to improve antibiotic prescribing have been effective in slowing down antibiotic resistance, however there has been little uptake of these strategies in Australian private hospitals. Needs, resources, and current barriers for these strategies will be investigated in the private hospital setting and results will be used to construct a program model that can be adopted by private h ....Inappropriate and overuse of antibiotics in hospitals has accelerated world-wide antimicrobial resistance. Strategies to improve antibiotic prescribing have been effective in slowing down antibiotic resistance, however there has been little uptake of these strategies in Australian private hospitals. Needs, resources, and current barriers for these strategies will be investigated in the private hospital setting and results will be used to construct a program model that can be adopted by private hospitals in AustraliaRead moreRead less
Improving The Treatment Of Neonatal Sepsis Through Vancomycin Pharmacokinetic And Pharmacodynamic Modelling
Funder
National Health and Medical Research Council
Funding Amount
$71,458.00
Summary
Our study will assess whether vancomycin, a key antibiotic used to treat severe infections in young infants, is best given as a continuous infusion or as multiple doses per day. We will determine which is the most effective method to achieve the target blood level of vancomycin and if current recommended target levels for vancomycin are appropriate for infants. Findings will be used to develop a bedside tool that will enable clinicians to tailor the dose of vancomycin to individual children.
Optimising Management Of Injection-related Infections In People Who Inject Drugs
Funder
National Health and Medical Research Council
Funding Amount
$132,743.00
Summary
People who inject drugs are a vulnerable group who are at increased risk of bacterial infections, which can lead to serious illness and death. This project aims to optimize management of bacterial infections in people who inject drugs. Measuring the current burden of infections, analysing different management strategies employed in hospitals and discussing attitudes and barriers to care with both healthcare workers and people who inject drugs will provide the evidence to optimize ongoing care.
Understanding The Disease Burden And Antibiotic Resistance In Patients With Bloodstream Infections Caused By Enterobacteriaceae In Australia
Funder
National Health and Medical Research Council
Funding Amount
$135,285.00
Summary
This study aims to establish the epidemiology of bloodstream infections caused by Enterobacteriaceae (enteric or gut bacteria) in Australia, by examining infection rates, types of antibiotic resistance present, and which treatments optimise clinical outcomes.
Establishing The Use Of Bacterial Genomics In Australia
Funder
National Health and Medical Research Council
Funding Amount
$157,669.00
Summary
We propose to establish a set of fully assembled reference genomes through new technologies and methods to analyse data from high throughput genome sequencing of important bacterial pathogens in Australia. We aim to demonstrate the capabilities of genome sequencing in clinical situations by comparing the genomes from clinical bacterial isolates to the established and annotated reference genomes.
Bowel cancer is the 2nd most common cause of cancer death in Australia. Rectal cancer represents 40% of these, and is more common in the elderly who are frequently unable to tolerate chemoradiation therapy. The Mutated in Colorectal Cancer gene (MCC) could become a predictor to chemoradiotherapy in up to 30% of these patients. A defective MCC in tumours can predict a good response to this treatment. Our project will potentially identify patients that are more sensitive to chemoradiotherapy and l ....Bowel cancer is the 2nd most common cause of cancer death in Australia. Rectal cancer represents 40% of these, and is more common in the elderly who are frequently unable to tolerate chemoradiation therapy. The Mutated in Colorectal Cancer gene (MCC) could become a predictor to chemoradiotherapy in up to 30% of these patients. A defective MCC in tumours can predict a good response to this treatment. Our project will potentially identify patients that are more sensitive to chemoradiotherapy and lead to a personalized treatment of rectal cancer.Read moreRead less
A New Therapeutic Monoclonal Antibody Targeting CD302 In Acute Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
This project will develop a new antibody treatment for Acute Myeloid Leukaemia. Antibody treatments help the body to attack the leukaemia using its immune system. The prognosis of this leukaemia is poor. Our current treatments use high dose chemotherapy and sometimes a stem cell transplant. Many patients cannot have the current therapy due to their age or other medical problems. A new antibody therapy may be used on its own or with other therapies to help more patients achieve remission.
Successful establishment of pregnancy requires a viable embryo and a receptive uterus. The contribution that reduced uterine receptivity makes to human infertility is unknown. IVF patients with implantation failure will be investigated using different approaches to identify gene pathways that are altered in reduced uterine receptivity. This study could lead to a clinical test for uterine receptivity and help to improve fertility treatment options for women with repeated implantation failure.
The Use Of Real-World Evidence To Support Regulatory And Reimbursement Decisions
Funder
National Health and Medical Research Council
Funding Amount
$91,538.00
Summary
Traditionally, medicines are studied extensively in clinical trials before they are widely available. More recently, some medicines have been allowed to enter the market without complete data on their benefits and risks. This means that these issues can only be studied once a medicine is on the market and used in routine clinical practice; this is referred to as real-world evidence. This research evaluates if this evidence is sufficient to prove that a medicine is safe and that it works
Lung cancer is the commonest cause of cancer death worldwide. There is growing interest in the genetic causes of lung cancer. The overall aim of this research is to gain a better understanding of the steps in the genetic pathway of lung cancer spread. This knowledge is essential in the development of new targeted therapies and improvement in lung cancer prognosis.